Galectin Therapeutics Inc. (GALT) Income Statement Analysis

See more : Nex Metals Explorations Limited (NME.AX) Income Statement Analysis – Financial Results

Complete financial analysis of Galectin Therapeutics Inc. (GALT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Galectin Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Centamin plc (CELTF) Income Statement Analysis – Financial Results
Hangzhou Steam Turbine Co., Ltd. (200771.SZ) Income Statement Analysis – Financial Results
Thelloy Development Group Limited (1546.HK) Income Statement Analysis – Financial Results
Raymond James Financial, Inc. (RJF) Income Statement Analysis – Financial Results
Kunshan Kersen Science & Technology Co.,Ltd. (603626.SS) Income Statement Analysis – Financial Results

Galectin Therapeutics Inc. (GALT)

Industry: Biotechnology

Sector: Healthcare

Website: https://galectintherapeutics.com

About Galectin Therapeutics Inc.

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000
Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	33.00K	32.00K	41.00K	36.00K	35.00K	0.00	1.00K	7.00K	7.00K	0.00	0.00	0.00	0.00	0.00	0.00	5.33M	6.46M	7.05M	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-33.00K	-32.00K	-41.00K	-36.00K	-35.00K	0.00	-1.00K	-7.00K	-7.00K	0.00	0.00	0.00	0.00	0.00	0.00	-5.33M	-6.46M	-7.05M	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Research & Development	32.13M	31.74M	23.82M	17.98M	7.47M	6.47M	11.72M	15.33M	13.11M	8.43M	5.69M	4.53M	3.55M	1.07M	1.11M	1.77M	2.05M	3.02M	3.04M	3.04M	1.95M	1.48M	893.46K	100.00K
General & Administrative	5.90M	6.62M	6.36M	5.47M	5.97M	7.13M	4.53M	6.16M	6.97M	7.01M	6.42M	5.37M	6.86M	3.82M	4.98M	3.55M	4.40M	4.03M	3.62M	4.26M	2.99M	1.80M	1.29M	70.00K
Selling & Marketing	44.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	5.94M	6.62M	6.36M	5.47M	5.97M	7.13M	4.53M	6.16M	6.97M	7.01M	6.42M	5.37M	6.86M	3.82M	4.98M	3.55M	4.40M	4.03M	3.62M	4.26M	2.99M	1.80M	1.29M	70.00K
Other Expenses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	200.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Expenses	38.07M	38.35M	30.18M	23.44M	13.44M	13.60M	16.25M	21.48M	20.08M	15.43M	12.10M	9.90M	10.41M	4.88M	6.09M	5.33M	6.46M	7.05M	6.66M	7.30M	4.94M	3.29M	2.18M	170.00K
Cost & Expenses	38.07M	38.35M	30.18M	23.44M	13.44M	13.60M	16.25M	21.48M	20.08M	15.43M	12.10M	9.90M	10.41M	4.88M	6.09M	5.33M	6.46M	7.05M	6.66M	7.30M	4.94M	3.29M	2.18M	170.00K
Interest Income	0.00	52.00K	3.00K	66.00K	231.00K	38.00K	24.00K	45.00K	52.00K	42.00K	16.00K	24.00K	18.00K	6.00K	3.00K	30.00K	102.00K	281.00K	111.00K	124.00K	68.93K	24.26K	24.92K	0.00
Interest Expense	2.56M	1.03M	489.00K	87.00K	87.00K	336.00K	12.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	350.00K	1.85M	0.00	0.00	3.88K	415.42K	0.00	0.00
Depreciation & Amortization	38.07M	32.00K	41.00K	36.00K	35.00K	1.00K	1.00K	7.00K	7.00K	10.00K	12.00K	9.00K	9.00K	12.00K	37.00K	49.00K	64.00K	67.00K	81.00K	81.00K	89.17K	211.18K	159.47K	-20.00K
EBITDA	-202.00K	-37.71M	-30.00M	-23.34M	-13.17M	-13.56M	-16.23M	-21.47M	-20.07M	-15.78M	-12.08M	-9.67M	-10.91M	-5.62M	-7.43M	-3.10M	-9.02M	-1.28M	-6.77M	-7.10M	-4.85M	-3.08M	-2.02M	-190.00K
EBITDA Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Income	-38.07M	-38.35M	-30.18M	-23.44M	-13.44M	-13.60M	-16.25M	-21.48M	-20.08M	-15.43M	-12.10M	-9.90M	-10.41M	-4.88M	-6.09M	-5.33M	-6.46M	-7.05M	-6.66M	-7.30M	-4.94M	-3.29M	-2.18M	-170.00K
Operating Income Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Total Other Income/Expenses	-2.99M	-424.00K	-348.00K	-21.00K	144.00K	-298.00K	12.00K	45.00K	52.00K	-358.00K	16.00K	224.00K	-506.00K	-746.00K	-1.37M	2.18M	-2.98M	3.86M	111.00K	124.00K	65.05K	-391.16K	0.00	-20.00K
Income Before Tax	-41.07M	-38.78M	-30.53M	-23.47M	-13.29M	-13.90M	-16.24M	-21.44M	-20.03M	-15.79M	-12.09M	-9.68M	-10.92M	-5.63M	-7.46M	-3.15M	-9.43M	-3.19M	-6.54M	-7.18M	-4.87M	-3.68M	0.00	-190.00K
Income Before Tax Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Income Tax Expense	0.00	424.00K	448.00K	51.00K	87.00K	-123.14K	24.00K	0.00	0.00	-52.00K	16.00K	200.00K	506.00K	746.00K	1.37M	-2.18M	2.98M	-3.86M	0.00	0.00	0.00	0.00	1.79M	0.00
Net Income	-41.07M	-39.20M	-30.98M	-23.52M	-13.38M	-13.90M	-16.24M	-21.44M	-20.03M	-15.79M	-12.09M	-9.68M	-10.92M	-5.63M	-7.46M	-3.15M	-9.43M	-3.19M	-6.54M	-7.18M	-4.87M	-3.68M	-3.97M	-190.00K
Net Income Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS	-0.74	-0.66	-0.53	-0.41	-0.26	-0.35	-0.46	-0.73	-0.83	-0.72	-0.72	-0.64	-0.91	-0.60	-0.93	-0.40	-1.45	-0.67	-1.44	-1.67	-1.37	-1.35	-1.75	-0.09
EPS Diluted	-0.74	-0.66	-0.53	-0.41	-0.26	-0.35	-0.46	-0.73	-0.83	-0.72	-0.72	-0.64	-0.91	-0.60	-0.93	-0.40	-1.45	-0.67	-1.44	-1.67	-1.37	-1.35	-1.75	-0.09
Weighted Avg Shares Out	60.16M	59.39M	58.53M	57.03M	52.24M	39.41M	35.52M	29.22M	24.12M	21.85M	16.87M	15.13M	11.99M	9.38M	8.05M	7.80M	6.50M	4.75M	4.55M	4.29M	3.56M	2.73M	2.27M	2.06M
Weighted Avg Shares Out (Dil)	60.16M	59.39M	58.53M	57.03M	52.24M	39.41M	35.52M	29.22M	24.12M	21.85M	16.87M	15.13M	11.99M	9.38M	8.05M	7.80M	6.50M	4.75M	4.55M	4.29M	3.56M	2.73M	2.27M	2.06M

GM sells out first-year production of GMC Hummer EV electric pickup in an hour - Electrek

October 21, 2020electrek.co

GM says that it has sold out, or more appropriately reserved out, the Edition 1, or the first year of production, of its new GMC Hummer EV electric pickup in just an hour. But how many trucks are we talking...

GMC Hummer EV vs Tesla Cybertruck vs Rivian R1T: price and specs comparison

October 21, 2020teslarati.com

Legacy automaker General Motors recently unveiled the Hummer EV, a monster of a vehicle that will be pitted against other all-electric trucks like the Tesla Cybertruck and the Rivian R1T. The Hummer EV isn’t just another rival in the sustainable...

GMC's All-Electric Hummer Pickup Highlights GM's New Strategy on EVs -- Update | MarketScreener

October 21, 2020marketscreener.com

GM unveils Hummer EV as 'world's first supertruck' for $112,600 starting in 2021

October 21, 2020cnbc.com

The new electric Hummer from General Motors will live up to the reputation of its predecessors for being capable and over the top but in different ways than the gas-guzzling vehicles that previously bore the name.